Search Results
Sep 02, 2026, 16:01 ET Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:
More news about: Neurocrine Biosciences, Inc.
Sep 02, 2026, 08:30 ET Tom Lee's Fundstrat Capital Completes August 2026 Rebalance For All Granny Shots ETFs
NVT (nVent Electric plc); PGEN (Precigen, Inc.); VICR (Vicor Corporation)Deletions: DPZ (Domino's Pizza, Inc.); ELF (e.l.f. Beauty, Inc.); NBIX (Neurocrine Biosciences, Inc.); ON (ON Semiconductor Corporation); UTHR (United Therapeutics Corporation); UUUU (Energy Fuels Inc.); WFRD (Weatherford
More news about: Fundstrat Capital
Aug 12, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of the KINECT-PRO™ Phase 4 open-label study results demonstrating that treatment with once-daily
More news about: Neurocrine Biosciences, Inc.
Aug 07, 2026, 11:20 ET /C O R R E C T I O N -- Fundstrat Capital/
and we keep this timing in mind when we rebalance."May 2026 Rebalance SummaryAdditions: CRDO, DKS, FSLR, MOD, NBIX, NTRA, RMBS, TTMI, ZETA, ZMDeletions: ARRY, AWI, CARR, DCI, H, IBP, ITT, UHSThe rebalance reflects updated positioning across
More news about: Fundstrat Capital
Aug 07, 2026, 08:30 ET Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon
More news about: Neurocrine Biosciences, Inc.
Jul 30, 2026, 16:01 ET Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
SAN DIEGO, July 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2026.
More news about: Neurocrine Biosciences, Inc.
Jul 23, 2026, 16:05 ET Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the company executes its next phase of
More news about: Neurocrine Biosciences, Inc.
Jul 21, 2026, 16:05 ET Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Samir Siddhanti as Chief Business Officer and a member of the company's executive Management Committee.
More news about: Neurocrine Biosciences, Inc.
Jul 09, 2026, 16:01 ET Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
30SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern
More news about: Neurocrine Biosciences, Inc.
Jul 01, 2026, 16:05 ET Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 16:10 ET Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment with
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 16:05 ET Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced clinical findings from the first retrospective case series in pediatric and adult patients with classic congenital adrenal hyperplasia
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 08:35 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new two-year data from the Phase 3 CAHtalyst® Pediatric study showing positive growth outcomes in children and adolescents
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 08:30 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new Phase 3 CAHtalyst® Adult study data demonstrating improved cardiometabolic outcomes alongside sustained glucocorticoid
More news about: Neurocrine Biosciences, Inc.
Jun 08, 2026, 16:05 ET Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new post-hoc data from the KINECT® 4 clinical trial demonstrating that adults with tardive dyskinesia (TD) treated with
More news about: Neurocrine Biosciences, Inc.
Jun 08, 2026, 08:30 ET Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new clinician-reported data in patients with intellectual and developmental disabilities demonstrating meaningful and rapid improvements
More news about: Neurocrine Biosciences, Inc.
Jun 03, 2026, 08:30 ET Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present multiple new analyses of key clinical and patient-reported outcomes up to two years of treatment with
More news about: Neurocrine Biosciences, Inc.
May 26, 2026, 16:01 ET Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:
More news about: Neurocrine Biosciences, Inc.
May 18, 2026, 16:05 ET Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from a clinician survey highlighting the functional impact experienced by patients with mild tardive dyskinesia
More news about: Neurocrine Biosciences, Inc.
May 18, 2026, 08:46 ET Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the company's leadership in endocrinology and rare disease.
More news about: Neurocrine Biosciences, Inc.
May 06, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of the first peer-reviewed expert recommendations to guide glucocorticoid dose reduction in patients with classic congenital
More news about: Neurocrine Biosciences, Inc.
May 05, 2026, 16:01 ET Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
BillionSAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026.
More news about: Neurocrine Biosciences, Inc.
May 05, 2026, 09:00 ET Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20 a.m. Pacific Time (2:20 p.m Eastern
More news about: Neurocrine Biosciences, Inc.
May 04, 2026, 08:30 ET Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey revealing the significant impact of tardive dyskinesia (TD) on people's ability to work, go
More news about: Neurocrine Biosciences, Inc.
May 04, 2026, 07:30 ET Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'2118 in adult participants.
More news about: Neurocrine Biosciences, Inc.